In this video, Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares some insights into the IMpactMF study (NCT04576156), which is comparing the use of imetelstat versus best available therapy (BAT) in patients with myelofibrosis (MF). This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.